Hemophilia
Odporúčame
Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.
Critical Overview of Clinical Studies on EHL FVIII Preparations
An international team of experts recently published a comprehensive work evaluating the methodology…
Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor…
Články k téme
Impact of Prophylaxis on Reducing the Risk of Neurological Problems Associated with Bleeding in Hemophilia A
Bleeding can also cause complications in the nervous system of hemophiliacs. The authors of…
Prophylaxis with Rurioctocog Alfa Pegol in Severe Hemophilia A
Rurioctocog alfa pegol represents a modern modality for the treatment of hemophilia from the…
Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were…
Practical Two-Point Pharmacokinetic Protocol in Hemophilia A
A recently published study confirmed the practicality of a shortened and simple…
Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
The possibility of actively preventing severe bleeding after a major cardiac surgical…
Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
Japanese authors investigated the mechanism of reduced efficacy of emicizumab in an adult…
Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A…
Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and…
Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for…
Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The…
Prihlásiť na odber spravodajcu
Kurzy k tejto téme
Najčítanejšie k tejto téme
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
- Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
Časopis k tejto téme
Súvisiace témy
Zaujímavé odkazy